Table 2 Strength of the statistical association between directional selection, absolute selection and tumor mutation burden with clinically relevant characteristics.

From: Strength of selection in lung tumors correlates with clinical features better than tumor mutation burden

Predictor

Clinically relevant feature

Age at diagnosis

Stage

Metastatic versus primary

ADENOCARCINOMA

Directional selection

rho = − 0.02, N = 685, p = 0.52

Spearman R = − 0.14, N = 69, p = 0.92

(− 0.067 ± 0.010 versus − 0.314 ± 0.089) t-test = 3.2, df = 474, p = 0.001

Absolute selection regardless of direction

rho = − 0.11, N = 685, p = 0.003

Spearman R = − 0.20, N = 69, p = 0.11

(0.153 ± 0.008 versus 0.326 ± 0.083) t-test = 2.9, df = 474, p = 0.004

Tumor mutation burden

rho = 0.15, N = 925, p = 0.0002

rho = − 0.06, N = 242, p = 0.38

(91.1 ± 7.7 versus 38.3 ± 22.4) t-test = 1.5, df = 1,137, p = 0.15

SQUAMOUS CELL CARCINOMA

Directional selection

rho = − 0.04, N = 713, p = 0.35

Spearman R = − 0.13, N = 129, p = 0.14

NA

Absolute selection regardless of direction

rho = − 0.01, N = 713, p = 0.85

Spearman R = − 0.43, N = 129, p = 0.0001

NA

Tumor mutation burden

rho = − 0.07, N = 747, p = 0.06

Spearman R = − 0.39, N = 747, p = 0.0004

NA

SMALL CELL LUNG CANCER

Directional selection

rho = − 0.11, N = 167, p = 0.16

Spearman R = − 0.06, N = 111, p = 0.51

(0.031 ± 0.031 versus − 0.757 ± 0.076) t-test = 11.1, df = 912, p < 1012

Absolute selection regardless of direction

rho = − 0.08, N = 167, p = 0.28

Spearman R = − 0.11, N = 111, p = 0.91

(0.146 ± 0.025 versus 0.806 ± 0.062) t-test = 11.7, df = 912, p < 1012

Tumor mutation burden

rho = − 0.20, N = 213, p = 0.003

Spearman R = − 0.05, N = 114, p = 0.59

(178.4 ± 10.9 versus 186.7 ± 24.1) t-test = 0.35, df = 1,137, p = 0.73

  1. NA—there were no samples from metastatic sites for squamous cell carcinoma.
  2. Significant values are in [bold].
Back to article page